An open study of vitamin D3 treatment in psoriasis vulgaris
- PMID: 3022784
- DOI: 10.1111/j.1365-2133.1986.tb06236.x
An open study of vitamin D3 treatment in psoriasis vulgaris
Abstract
Active forms of vitamin D3, 1 alpha-hydroxyvitamin D3 and 1 alpha,25-dihydroxyvitamin D3, were administered in an open-design study to 40 patients with psoriasis vulgaris in three ways: to 17 patients 1 alpha-hydroxyvitamin D3 was given orally at a dose of 1.0 micrograms/day for 6 months, to four patients 1 alpha,25-dihydroxyvitamin D3 was given orally at a dose of 0.5 microgram/day for 6 months, and 19 patients were given 1 alpha,25-dihydroxyvitamin D3 applied topically at concentration of 0.5 microgram/g of base for 8 weeks. Improvement was observed at the end of the individual study periods in 13 (76%) patients in Group 1 with a mean period of treatment (+/- SD) of 2.7 +/- 0.6 months, in one patient in Group 2 at 3 months after the start of treatment, and in 16 (84%) patients in Group 3 when the chemical was applied for 3.3 +/- 1.2 weeks. No side-effects were observed in any of these trials. These data suggest that psoriasis may respond to active metabolites of vitamin D3 and that abnormalities in vitamin D metabolism or in responsiveness of the skin cells to active metabolites of vitamin D may be involved in the pathogenesis of this skin disease.
Similar articles
-
Psoriasis and vitamin D3. A review of our experience.Arch Dermatol. 1989 Feb;125(2):231-4. Arch Dermatol. 1989. PMID: 2536537 Clinical Trial.
-
Treatment of psoriasis vulgaris by oral administration of 1 alpha-hydroxyvitamin D3--open-design study.Calcif Tissue Int. 1986 Sep;39(3):209-12. doi: 10.1007/BF02555120. Calcif Tissue Int. 1986. PMID: 3093033
-
Metabolites of vitamin D in human vitamin-D deficiency: effect of vitamin D3 or 1,25-dihydroxycholecalciferol.Lancet. 1980 Sep 20;2(8195 pt 1):612-5. doi: 10.1016/s0140-6736(80)90283-4. Lancet. 1980. PMID: 6107407 Clinical Trial.
-
Skin as the site of vitamin D synthesis and target tissue for 1,25-dihydroxyvitamin D3. Use of calcitriol (1,25-dihydroxyvitamin D3) for treatment of psoriasis.Arch Dermatol. 1987 Dec;123(12):1677-1683a. Arch Dermatol. 1987. PMID: 2825606 Review.
-
An update on vitamin D3 analogues in the treatment of psoriasis.Skin Pharmacol Appl Skin Physiol. 1998 Jan-Feb;11(1):2-10. doi: 10.1159/000029803. Skin Pharmacol Appl Skin Physiol. 1998. PMID: 9603664 Review.
Cited by
-
Vitamin D Signaling in Psoriasis: Pathogenesis and Therapy.Int J Mol Sci. 2022 Aug 2;23(15):8575. doi: 10.3390/ijms23158575. Int J Mol Sci. 2022. PMID: 35955731 Free PMC article. Review.
-
Dietary Intervention and Supplements in the Management of Psoriasis: Current Perspectives.Psoriasis (Auckl). 2022 Jun 22;12:151-176. doi: 10.2147/PTT.S328581. eCollection 2022. Psoriasis (Auckl). 2022. PMID: 35769285 Free PMC article. Review.
-
Safety Data in Patients with Autoimmune Diseases during Treatment with High Doses of Vitamin D3 According to the "Coimbra Protocol".Nutrients. 2022 Apr 10;14(8):1575. doi: 10.3390/nu14081575. Nutrients. 2022. PMID: 35458137 Free PMC article.
-
The Epidermis: Redox Governor of Health and Diseases.Antioxidants (Basel). 2021 Dec 26;11(1):47. doi: 10.3390/antiox11010047. Antioxidants (Basel). 2021. PMID: 35052551 Free PMC article. Review.
-
Oral and Topical Vitamin D, Sunshine, and UVB Phototherapy Safely Control Psoriasis in Patients with Normal Pretreatment Serum 25-Hydroxyvitamin D Concentrations: A Literature Review and Discussion of Health Implications.Nutrients. 2021 Apr 29;13(5):1511. doi: 10.3390/nu13051511. Nutrients. 2021. PMID: 33947070 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
